基于不同病毒载体的内皮抑素基因治疗的研究进展  

Research Progress on Gene Therapy of Endostatin Based on Different Viral Vectors

作　　者：徐文佳 王凤山 XU Wen-jia;WANG Feng-shan(Institute of Biochemical and Biotechnological Drugs,School of Pharmaceutical Sciences,Cheeloo College of Medicine,Shandong University,Jinan 250012,China)

机构地区：[1]山东大学齐鲁医学院药学院生化与生物技术药物研究所,济南250012

出　　处：《中国药学杂志》2021年第24期1962-1967,共6页Chinese Pharmaceutical Journal

基　　金：国家自然科学基金项目资助(81273417)。

摘　　要：内皮抑素作为抗血管生成活性最强的内源性蛋白之一,自发现以来一直备受关注,但短的半衰期、稳定性差限制了它的使用。基因治疗作为一种将外源蛋白基因导入靶细胞,在靶细胞内实现稳定而持续表达的治疗方法,为利用内皮抑素治疗疾病提供了一个可克服内皮抑素缺点的途径。内皮抑素的基因治疗中变数最大的为基因传递系统,而在基因传递系统中病毒载体最为常用。因此,本研究聚焦于不同的病毒载体,综述近十年来内皮抑素基因治疗的发展现状和发展趋势。Endostatin,as one of the endogenous proteins with the strongest anti-angiogenic activity,has attracted much attention since its discovery.However,its shortcomings such as short half-life and instability limit its use.Gene therapy,as a therapeutic method for introducing foreign protein genes into target cells and achieving stable and continuous expression in target cells,provides a way to overcome the shortcomings of endostatin in using it to treat diseases.The most variable factors in endostatin gene therapy are the gene delivery systems.Meanwhile,among the gene delivery systems,viral vectors are the most commonly used ones.Therefore,this review focuses on different viral vectors and discusses the development status and trends of endostatin gene therapy in the past decade.

关 键 词：内皮抑素 基因治疗 病毒载体 联合治疗 临床试验 

分 类 号：R915[医药卫生—微生物与生化药学]